SCHEMBL17028441

SCHEMBL17028441

CC(=O)CC(O[Si](C)(C)C(C)(C)C)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17028440 1.00 ALDH1A1 (0.33) ALDH1A1TDP1
SCHEMBL16503512 0.79 LMNA (0.33)
SCHEMBL6496531 0.78 ALDH1A1 (0.39) ALDH1A1TDP1
SCHEMBL6484089 0.78 ALDH1A1 (0.39) ALDH1A1TDP1
SCHEMBL13906596 0.74 LMNA (0.35) ALDH1A1TDP1
SCHEMBL13906594 0.74 LMNA (0.35) ALDH1A1TDP1
SCHEMBL17911651 0.74 LMNA (0.35) ALDH1A1TDP1
SCHEMBL5702689 0.73
SCHEMBL14267356 0.73 ALDH1A1 (0.40) ALDH1A1TDP1
SCHEMBL6525612 0.72 ATM (0.39) ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718645-B2 Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-08-08 US disclosed
EP-3107919-B1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT UNIV FLORIDA (US) 2021-01-27 EP disclosed
US-20200317732-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2020-10-08 US disclosed
US-20190241611-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2019-08-08 US disclosed
US-20170057996-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2017-03-02 US disclosed
EP-3107919-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT University of Florida Research Foundation (US) 2016-12-28 EP disclosed
WO-2015127161-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718645-B2 Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment NFATC1, MCL1, ICOS ALDH1A1 2615/4885TDP1 3096/4885
US-20200317732-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT NFATC1, MCL1, ICOS ALDH1A1 2615/4885TDP1 3096/4885
US-20170057996-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT NFATC1, MCL1, ICOS ALDH1A1 2615/4885TDP1 3096/4885
US-20190241611-A1 MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT NFATC1, MCL1, ICOS ALDH1A1 2615/4885TDP1 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.